PTPN1 and obesity disorder: α-Glucosidase and PTP1B are the key targets to treat diabetes and obesity [9] and compounds with dual inhibitory activity against these enzymes exhibit synergistic effects to prevent hyperglycaemia, in turn, effectively improve insulin sensitization [10].